Pete Anevski, Progyny CEO
October 30, 2023 02:47 PM EDTUpdated November 6, 08:44 AM
Health Tech

Fer­til­i­ty ben­e­fits com­pa­ny Prog­y­ny shares how it han­dles start­up val­u­a­tions when look­ing for deals

Lydia Ramsey Pflanzer

Deputy Editor

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

When Prog­y­ny went pub­lic in 2019 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times